144 ·Filed Jun 3, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001973379-26-000219
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine, pre-planned insider sale under a 10b5-1 plan by a director. The small dollar amount and plan adoption date over a year ago indicate no material non-public information concern. No action warranted.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
QURE ▲ +65.86% at T+60d
NEUTRAL call ✓ call won +65.86% · α vs SPY +63.36% · entry $29.88 → $49.56
Entry anchored
Jun 3, 03:58 PM ET
via exchange tick
T+1d
-6.33%
call -6.33% · α -6.72%
$27.99
settled 4mo ago
T+5d
-10.24%
call -10.24% · α -6.42%
$26.82
settled 4mo ago
T+20d
+39.93%
call +39.93% · α +40.93%
$41.81
settled 3mo ago
T+60d
+65.86%
call +65.86% · α +63.36%
$49.56
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Director Jack Kaye filed a Form 144 notice of intent to sell 2,645 ordinary shares of uniQure N.V., valued at approximately $79,384, on June 3, 2026. The sale is pursuant to a Rule 10b5-1 trading plan and follows a stock option exercise. The small size relative to the company's $1.7B market cap makes this a routine insider transaction with minimal market impact.

Key Facts

  • Director Jack Kaye filed Form 144 to sell 2,645 ordinary shares.
  • Estimated aggregate value of the proposed sale is $79,384.
  • Sale is executed pursuant to a Rule 10b5-1 trading plan adopted on June 16, 2025.
  • Transaction follows a stock option exercise and is for cash.
  • The sale represents approximately 0.0004% of the company's $1.7B market cap.

Financial Impact

Proposed sale of 2,645 shares valued at $79,384, representing a negligible fraction of market cap.

dilution

Risk Factors

  • Insider selling pattern could escalate if additional directors or officers file similar notices.
  • Form 144 is only an intent to sell; the actual sale may not occur.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001973379-26-000219
Document: 0001973379-26-000219-index.html0001973379-26-000219
Document: 0001973379-26-000219.txt0001973379-26-000219
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access